Amid the dozens of publicly traded firms in Minnesota, Baudette-based ANI Pharmaceuticals Inc. often flies under the radar. The pharmaceutical company about five hours north of Minneapolis has grown ...

ANI Pharmaceuticals, Inc. delivered robust 2025 results and issued bullish 2026 guidance. Learn more about ANIP stock here.

ANI is growing its capabilities and pipeline with an acquisition. The company has signed a definitive agreement to acquire Novitium Pharma for $163.5 million, including $89.5 million in cash and $74 ...

Indian news agency ANI has filed a lawsuit against OpenAI, alleging copyright infringement. ANI claims OpenAI used its content without permission to train its AI chatbot, ChatGPT, and even attributed ...

BAUDETTE, Minn., Aug. 08, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced financial results and business highlights for the second quarter ended ...

What Happened? Shares of specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) jumped 13.6% in the afternoon ...

Oregon-based Stonepine Capital Management sold all 38,597 shares of its ANI Pharmaceuticals shares in the third quarter. The shares were worth about $2.52 million. The move marked a full exit from ANI ...

-- ANI Pharmaceuticals appoints Mary Pao, M.D., Ph.D., as Chief Medical Officer, Rare Disease, and Elizabeth Powell, J.D., as Chief Compliance Officer and Head of ...

ANI Pharmaceuticals has paid $17.25 million to buy out royalty obligations for ILUVIEN and YUTIQ, enhancing financial flexibility. ANI Pharmaceuticals incurred a one-time payment of $17.25 million to ...